2018.Oct.29
OBI Pharma Australia Pty Ltd announces the clearance of Adogloxad Simolenin (OBI-822) for a Phase III clinical study in Australia
Date of occurrence of the event: Oct 29, 2018 Company name: OBI Pharma Australia Pty Ltd Relationship to the Company (please enter “head office” or “subsidiaries”): subsidiary Reciprocal shareholding ratios: 100% Cause of occurrence: An application of a P3 clinical study for Adogloxad Simolenin (OBI-822), an investigational drug in development by OBI, was submitted by […]
This article is password protected.
To view the content, please enter your password in the field below